<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862741</url>
  </required_header>
  <id_info>
    <org_study_id>NX-13-1b</org_study_id>
    <nct_id>NCT04862741</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis</brief_title>
  <official_title>A Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Landos Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Landos Biopharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, randomized, double-blind, multicenter dose-ranging study to evaluate the&#xD;
      safety, tolerability, and PK of NX-13. Approximately 40 subjects will be randomized in a&#xD;
      3:3:3:1 ratio to receive 1 of 3 NX-13 treatment regimens (NX-13 250 mg IR, 500 mg IR, 500 mg&#xD;
      MR) (12 evaluable subjects at each of the 3 dose levels) or placebo (4 subjects), once daily&#xD;
      for 28 consecutive days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following screening period (up to 28 days in length), a total of 40 subjects are planned to&#xD;
      be enrolled into this study from multiple sites in the United States, Australia, New Zealand,&#xD;
      and Moldova. Eligible subjects will be randomized in a 3:3:3:1 ratio to receive 1 of 3 NX-13&#xD;
      treatment regimens (NX-13 250 mg IR, 500 mg IR, 500 mg MR) or placebo via a&#xD;
      computer-generated interactive web response system (IWRS). Each of the NX-13 treatment groups&#xD;
      will comprise 12 subjects and 4 subjects will be randomized to receive placebo. The study&#xD;
      will include a maximum of 25% of subjects who have had prior exposure to biologic therapy for&#xD;
      UC.&#xD;
&#xD;
      Dosing will extend over a 28-day period at each dose level. Subjects will receive the first&#xD;
      dose of study drug in clinic on Day 1 (Visit 2) and Day 28 (Visit 4/EOT) but will&#xD;
      self-administer IP at home once daily for the remaining dosing days. The study duration will&#xD;
      be approximately 63 days: Screening Period (28 days) + Treatment Period (28 days) + Safety&#xD;
      Follow-up (7 days after last dose). There will be a follow-up visit on Day 35 (Visit 5).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events after multiple oral dose administration of NX-13 in subjects with active ulcerative colitis (UC)</measure>
    <time_frame>63 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of NX-13 after multiple oral dose administration in subjects with active UC</measure>
    <time_frame>63 days</time_frame>
    <description>- NX-13 concentrations in plasma, colonic tissue biopsies, and feces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters - Time to maximum concentration (tmax);</measure>
    <time_frame>63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters- Maximum concentration (Cmax)</measure>
    <time_frame>63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters- Area under the concentration-time curve from time 0 to last measurable time-point (AUC0-tlast);</measure>
    <time_frame>63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters-Terminal half-life (t1/2)</measure>
    <time_frame>63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters- clearance (CL);</measure>
    <time_frame>63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters- Vz, apparent volume of distribution during terminal phase.</measure>
    <time_frame>63 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>NX-13 250mg IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NX-13 500mg IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NX-13 500mg MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NX-13 250mg IR</intervention_name>
    <description>Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.</description>
    <arm_group_label>NX-13 250mg IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NX-13 500mg IR</intervention_name>
    <description>Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.</description>
    <arm_group_label>NX-13 500mg IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NX-13 500mg MR</intervention_name>
    <description>Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.</description>
    <arm_group_label>NX-13 500mg MR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  male and female subjects aged 18 to 75 years (inclusive) with a diagnosis of UC ≥ 90&#xD;
             days before screening;&#xD;
&#xD;
          -  active UC defined as a total Mayo Score of 4 to 10 (inclusive), at baseline, with a&#xD;
             Mayo endoscopic subscore (MES) ≥ 2 confirmed by a central reader;&#xD;
&#xD;
          -  baseline fecal calprotectin ≥ 250 μg/g;&#xD;
&#xD;
          -  biologic-naïve or having stopped biologic therapy ≥ 8 weeks before the start of the&#xD;
             study;&#xD;
&#xD;
          -  5-aminosalicylates must be stable for ≥ 1 month prior to randomization.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Crohn's disease (CD), indeterminate colitis, or presence or history of fistula with&#xD;
             CD;&#xD;
&#xD;
          -  a history of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or&#xD;
             stoma;&#xD;
&#xD;
          -  history of or at imminent risk of colectomy;&#xD;
&#xD;
          -  history of or current colonic dysplasia ;&#xD;
&#xD;
          -  recent history (within 2 years prior to randomization) or current adenomatous colonic&#xD;
             polyps;&#xD;
&#xD;
          -  treatment with an immunosuppressant within 3 months of randomization;&#xD;
&#xD;
          -  bacterial or parasitic pathogenic enteric infection;&#xD;
&#xD;
          -  live virus vaccination within 1 month prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyoti Chauhan</last_name>
    <role>Study Director</role>
    <affiliation>Landos Biopharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyoti Chauhan</last_name>
    <phone>5402182232</phone>
    <email>jyoti@landosbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josep Bassaganya-Riera</last_name>
    <email>jbr@landosbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Avant Research Associates LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Om Research LLC</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jatinder S Pruthi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allameh Medical Corporation</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Allamehzadeh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Medical Research Associates, Inc.</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Calin Arimie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of California</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeraj Marameddy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>I.H.S Health LLC</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Lateef, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Crohn's and Colitis Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kerman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valencia Medical and Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inti Fernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endoscopic Research, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Levine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Care Access</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Moore, DO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Pensacola, P.A.</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Newman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Gastroenterology, P.C.</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rausher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Care Access</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Crespin, MD, MBA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Care Access</name>
      <address>
        <city>Lumberton</city>
        <state>North Carolina</state>
        <zip>28538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwadwo Agyei-Gyamfi, MD, MHS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Optimed Research, LTD</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald McNeil, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Care Access</name>
      <address>
        <city>Pottsville</city>
        <state>Pennsylvania</state>
        <zip>17901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenn S. Freed, DO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galen Medical Group</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Schmitt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avant Research Associates, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78742</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Mehta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatics, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James A. Maher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LinQ Research, LLC</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jignesh Shah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Star Research Institute, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff S. Bullock, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria Gastroenterology</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dharmenda Verma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Care Access Research, Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peder Pedersen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Enterprise I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital of Dnipropetrovsk Regional Counsil, cont.</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olha Khodasenko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olha Romaniv</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center 'Ok!Clinic+' of Copmany with limited liability &quot;International institue of Clinical Research&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svitlana Skybalo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital &quot;Feofaniya&quot; of State Management of Affairs, Center of Gastroenterology and Endocrinology</name>
      <address>
        <city>Kyiv</city>
        <zip>03143</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Dorohavtseva, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise of Kyiv Regional Council Kyiv Regional Hospital, Department of Therapy</name>
      <address>
        <city>Kyiv</city>
        <zip>04078</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetiana Lohdanidi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-Commercial Enterprise of M.I. Pyrohov Vinnytsia Regional Clinical Hospital of Vinnytsia Regional Council</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliia Kizlova, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise Vinnytsia City Clinical Hospital #1, Department of Gastroenterology</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halyna Tomashkevych, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center of Limited Liability Company Gastroenterology Center IBD TEAM</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69121</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viacheslav Neshta, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise O.F. Herbachevskyi Regional Clinical Hospital of Zhytomyr Regional Council</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iurii Bilotskyi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

